Spastic Paraplegia Type 5A, Recessive
Conditions
Keywords
spastic paraplegia, metabolism, magnetic resonance imaging, Expanded Disability Status Scale (EDSS), brain, spine
Brief summary
This is a research study aiming to identify imaging biomarkers in patients diagnosed with spastic paraplegia type 5 (SPG5)
Detailed description
The aim of this study is to identify robust and reliable imaging biomarkers of disease by using novel macrostructural (volumetry), microstructural (fiber tractography) and spectroscopy (metabolites) methods to calculate SPG5 patients biometrics using a commercially available medical software Brain Quant (licence BT-BQ-001-START, market CAIH, CE12331), an approach with a larger effect size than conventional methods. This study will recruit 10 SPG5 patients. Each participant will be invited to a one-day session during which a clinical examination will performed and an EDSS score will be assigned, followed by a brain and a spine MRI/MRS examination. Clinical implications: This study will define biomarkers that can be quantified in SPG5 patients and that could be used as read-outs to assay therapeutic effects in clinical trials focused on SPG5 patients
Interventions
OTHERCerebral and spinal cord magnetic resonance imaging
Cerebral and spinal cord magnetic resonance imaging (without injection of contrast medium). Patient's data will be compared to calibrated data from the commercially available medical software Brain Quant (licence BT-BQ-001-START, market CAIH, CE12331).
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 18 years of age * Signature of the informed consent * Covered by social security * SPG5 patients identified with two mutations in the CYP7B1 gene
Exclusion criteria
* Contra-indications to MRI (claustrophobia, metallic or material implants) * Additional psychiatric or neurological conditions / additional major comorbidities * History of severe head injury * Participation in another trial (except observational trial) * Pregnancy and breastfeeding * Inability to understand information about the protocol * Persons under AME * Persons deprived of their liberty by judicial or administrative decision * Adult subject under legal protection or unable to consent * Unwillingness to be informed in case of abnormal MRI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the cross-sectional area in the spine of SPG5 patients | 1 day | An MRI analysis will be performed at the level of the spinal cord of SPG5. This analysis will quantify the cross-sectional area, in pixel, of each vertebra in each imaged individual, using the commercially available medical software Brain Quant (licence BT-BQ-001-START, market CAIH, CE12331) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the cross-sectional area of the segmented white matter and gray matter in the spine of SPG5 patients | 1 day | An MRI analysis will be performed at the level of the spinal cord SPG5 patients. This analysis will quantify the cross-sectional area, in pixel2, of the segmented white matter and gray matter in each imaged individual. |
| Changes in the diffusion tensor imaging (DTI) of the spine in SPG5 patients | 1 day | An MRI analysis will be performed at the level of the spinal cord of and SPG5 patients. This analysis will allow the quantification of fraction anisotropy (FA) and radial diffusivity (RD) in different regions of the spine |
| Changes in metabolic profiles in the spine of SPG5 patients | 1 day | A combined MRI/MRS analysis will be performed at the level of the spinal cord of SPG5 patients. This analysis will allow to quantify in parts per million (ppm) the ratios of the following metabolites in the spine: N-acetylaspartate, myo-inositol, choline and creatine. |
| Changes in brain volume brain in SPG5 patients | 1 day | An MRI analysis will be performed at the level of brain of SPG5 patients. This analysis will allow the quantification in voxels of brain volume. |
| Changes in the diffusion tensor imaging (DTI) in the brain of SPAG5 patients | 1 day | An MRI analysis will be performed at the level of the brain of SPG5 patients. This analysis will allow the quantification of FA and RD in different regions of the brain. |
| Validation of correlation between Expanded Disability Status Scale (EDSS) score severity and severity of morphological and/or metabolic changes | 1 day | An EDSS score will be assigned to each participant after clinical evaluation. Each participant's biomarker severity scores will be compared to his respective EDSS score and determine whether EDSS severity score correlates with biomarker severity. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. EDSS steps 1.0 to 4.5 refer to people who are able to walk without any aid and is based on measures of impairment in eight functional systems (FS). EDSS steps 5.0 to 9.5 are defined by the impairment to walking. |
Countries
France
Outcome results
None listed